Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
Go back to Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease| INSMED (NASDAQ: INSM) | Delayed: 95.80 -2.65 (2.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.45 | 52 Week High | $19.30 | |||
| Open | $100.11 | 52 Week Low | $9.02 | |||
| Day High | $100.25 | P/E | N/A | |||
| Day Low | $94.00 | EPS | $-1.69 | |||
| Volume | 23,379,310 | |||||
